Short-term safety data for ipamorelin in humans from a real-world clinical trial in surgical patients showed an adverse event rate no higher than placebo. However, this reassuring finding comes from a narrow, tightly monitored population for a short duration. Several specific questions about side effects that people commonly ask — water retention, hunger, cortisol, cancer risk — require delving into separate studies on the broader ghrelin receptor system that ipamorelin activates. The ipamorelin basic studies themselves did not directly measure all of these outcomes.
What are the side effects of Ipamorelin?
The most direct clinical safety data available for ipamorelin come from a randomized, placebo-controlled, phase 2, multicenter trial in patients recovering from bowel resection surgery. Ipamorelin was administered as an intravenous infusion twice daily for up to seven days. In this study, the overall incidence of any treatment-related adverse event was 87.5% in the ipamorelin group, compared with 94.8% in the placebo group. This indicates that adverse events were not reported more frequently with ipamorelin than with placebo in this specific, hospitalized, closely monitored surgical population [1].
It's important to understand what this discovery says and what it doesn't say. It reflects a short-term, intravenous, medically supervised use case in individuals recovering from surgery. It does not represent long-term safety data, self-administered subcutaneous use, or use in a healthy population seeking wellness or performance benefits. The study also did not provide a detailed, itemized breakdown of every specific minor symptom experienced by participants.
Beyond this study, ipamorelin's primary pharmacological studies established something reassuring. It does not significantly increase cortisol, ACTH, prolactin, FSH, LH, or TSH, even at doses far exceeding what is needed to trigger growth hormone release. This is a noteworthy point of reassurance regarding several specific hormonal side effects, discussed in more detail below [2].
Does Ipamorelin cause water retention, flushing, or bloating?
No study identified in the peer-reviewed literature reviewed for this article specifically measured water retention, redness, swelling, rash, headaches, or injection site burning as outcomes in individuals using ipamorelin. These specific symptoms, therefore, remain unconfirmed by direct clinical data, neither established nor ruled out. As for redness specifically, there is a genuine, scientifically plausible mechanism worth explaining. Ipamorelin acts by activating the ghrelin receptor. Separate, peer-reviewed studies of ghrelin itself, the natural hormone to which this receptor evolved to respond, have documented that ghrelin acts as a vasodilator. It reduces vascular resistance by acting directly on the smooth muscle of blood vessels [3].
Since dilated blood vessels near the skin’s surface are a common, well-established mechanism behind flushing in medicine more broadly, this offers a likely explanation for why some people report facial flushing or erythema after ipamorelin administration. However, it is important to be precise. This combines two separate lines of research—the documented vasodilatory effect of ghrelin and the known activation of the same receptor by ipamorelin—rather than a study that directly measured flushing specifically following an injection of ipamorelin.
Water retention and bloating are not addressed by any dedicated ipamorelin study identified herein. The general physiology of growth hormone, discussed in relation to CJC-1295 elsewhere in this series, documents fluid retention as a recognized effect of elevated growth hormone activity. However, this has not been separately confirmed for ipamorelin via direct measurement.
Does Ipamorelin cause hunger, weight gain, or insulin resistance?
This is one of the more evidence-based concerns regarding side effects specific to ipamorelin. It is directly and logically linked to the receptor system that this compound activates. Ghrelin, a natural hormone whose receptor is mimicked by ipamorelin, is widely documented in endocrinological studies as the body’s primary „hunger hormone.” A comprehensive scientific review has explained that ghrelin is the only known, peripherally produced hormone that increases appetite and the resulting food intake. It works by activating specific appetite-stimulating neurons in the arcuate nucleus of the brain [4].
Since ipamorelin activates the same receptor pathway, the appetite-stimulating effect is mechanistically probable. This expectation is directly supported by animal data. Studies examining the growth hormone-independent effects of GH secretagogues have shown that ipamorelin treatment in mice increased food intake and serum leptin levels, along with increased body weight and fat mass. This occurred through a mechanism that appeared to be independent of growth hormone itself [5].
This is a truly significant discovery. It suggests that ipamorelin's activation of the appetite-related ghrelin pathway may work against, rather than for, the goal of weight management. This is a point worth taking seriously, considering how differently this compound is often marketed.
Specifically regarding insulin and blood sugar, separate animal studies analyzed the direct effect of ipamorelin on the pancreas. They showed that ipamorelin induced significant increases in insulin secretion from pancreatic tissue in both normal and diabetic rats via calcium channel and adrenergic receptor pathways [6]. This finding describes stimulated insulin release, not a documented effect on insulin resistance. It is worth noting, however, that these remain animal tissue studies, not clinical trials in humans measuring blood sugar control or insulin sensitivity over time.
None of the human studies identified in this article measured changes in blood pressure associated with ipamorelin. It is worth noting, however, that the ghrelin-related vasodilation mechanism discussed above would theoretically be more consistent with lowered, rather than elevated, blood pressure. This point remains speculative without direct measurement.
Does Ipamorelin cause cancer, or problems with cortisol or prolactin?
Regarding cortisol and prolactin specifically, ipamorelin has a genuine, well-documented calming effect. Its basic pharmacological profile directly tested and confirmed that it does not significantly raise either of these hormones, even at doses over 200 times higher than needed for its growth hormone effect. This clearly distinguishes it from older generation compounds like GHRP-2 and GHRP-6, which did raise both [2]. This is one of ipamorelin's most cited and best-supported safety features.
Regarding cancer risk, no study identified in these investigations directly measured cancer incidence in individuals using ipamorelin. Therefore, this question cannot be answered by direct human evidence.
What can be said, in line with the broader discussion of this topic regarding CJC-1295 elsewhere in this series, is this: The downstream effect of ipamorelin on IGF-1, which is hypothesized but not directly confirmed by measurements in humans, as discussed in an earlier article, would raise the same general, theoretical concern that applies to the growth hormone-IGF-1 axis more broadly. IGF-1 is recognized in mainstream endocrinology as having cell-growth-stimulating effects. A 2026 review covering performance-enhancing peptides acting on this axis, including ipamorelin, described such concerns as „biologically plausible but unproven.” This is an appropriately cautious characterization that applies here as well [7].
As for anxiety, insomnia, and fertility, no dedicated study of ipamorelin has addressed these specific outcomes in humans. The ghrelin receptor system has been documented in broader studies as playing a role in brain pathways associated with stress and anxiety [8]. However, this describes the known biology of the general receptor system, rather than a finding specific to ipamorelin itself.
Limitations of current evidence
The short-term safety of ipamorelin in a monitored surgical population is documented by real-world clinical trial data [1]. Its lack of significant effect on cortisol and prolactin is well-established by its fundamental pharmacology [2].
Several specific side effects that people commonly inquire about, including water retention, flushing, bloating, skin reactions, blood pressure, anxiety, insomnia, and fertility, have not been directly measured in a dedicated ipamorelin study. Conclusions about them are based on mechanistic reasoning combined with the broader ghrelin receptor system, rather than direct clinical findings.
The appetite-stimulating and fat-promoting effects observed in animal studies represent a real and concrete concern that contradicts common marketing claims about this relationship [5].
Disclaimer
Ipamorelin is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory authority for any human use, and no regulatory authority has established an official, comprehensive safety profile for this compound outside the narrow context of surgical regeneration, where it has been most directly studied. It is not manufactured or sold under the quality and safety oversight that applies to approved pharmaceuticals. The safety information in this article is derived from a limited number of clinical and animal studies, as well as recent scientific reviews, and does not establish a comprehensive safety profile for humans regarding general or long-term use. This article is provided solely for general educational and informational purposes, reflects the state of the published scientific literature at the time of writing, and does not constitute medical advice. Anyone experiencing any side effects while using this or any other peptide compound should immediately consult a licensed healthcare professional.
References
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[2] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
[3] DeBoer, M. D. (2012). The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: Efficacy and mechanism. Current Pharmaceutical Design, 18(31), 4779–4799. https://doi.org/10.2174/138161212803216951
[4] Howick, K., Griffin, B. T., Cryan, J. F., & Schellekens, H. (2017). From belly to brain: Targeting the ghrelin receptor in appetite and food intake regulation. International Journal of Molecular Sciences, 18(2), Article 273. https://doi.org/10.3390/ijms18020273
[5] Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065
[6] Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-induced insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403–406.
[7] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, Article 1822475. https://doi.org/10.3389/fendo.2026.1822475
[8] Howick, K., Griffin, B. T., Cryan, J. F., & Schellekens, H. (2017). From belly to brain: Targeting the ghrelin receptor in appetite and food intake regulation. International Journal of Molecular Sciences, 18(2), Article 273. https://doi.org/10.3390/ijms18020273